Inhibitory effect of a new gossypol derivative apogossypolone （ApoG2） on xenograft of human prostate cancer cell line PC-3

Zhang Xianqing1; Huang Xiaofeng2; Mu Shijie1; Chen Rui1; An Qunxing1; Xia Aijun1; Wu Daocheng3 1Department of Blood Transfusion; Xijing Hospital; Fourth Military Medical University; Xi’an 710032; China 2Central Laboratory; Fourth Military Medical University; Xi’an 710032; China 3Key Laboratory of Biomedical Information Engineering of Ministry of Education; Xi’an Jiaotong University; Xi’an 710038; China

Your Location：

Home >

Browse articles >

Inhibitory effect of a new gossypol derivative apogossypolone （ApoG2） on xenograft of human prostate cancer cell line PC-3

Updated：2026-03-12

- Inhibitory effect of a new gossypol derivative apogossypolone （ApoG2） on xenograft of human prostate cancer cell line PC-3
- Military Medical Research Vol. 24, Issue 5, Pages: 274-282(2009)
- Affiliations：
- Author bio：
- Funds：
- DOI：
  CLC： R737.25
- Published：2009
- Accepted：
Scan QR Code
[1].Inhibitory effect of a new gossypol derivative apogossypolone (ApoG2) on xenograft of human prostate cancer cell line PC-3[J].Journal of Medical Colleges of PLA,2009,24(05):274-282.
DOI：

[1].Inhibitory effect of a new gossypol derivative apogossypolone (ApoG2) on xenograft of human prostate cancer cell line PC-3[J].Journal of Medical Colleges of PLA,2009,24(05):274-282. DOI：

摘要

Abstract

Objective: To investigate the inhibitory effect of apogossypolone （ApoG2） on prostate cancer cell line PC-3 in vivo

and explore its mechanism. Methods: The models of transplantation tumors in Balb/c nu/nu mice were established via subcutaneous injection of PC-3 cells and the tumor-transplanted mice were divided into 4 groups: control group and three ApoG2 treatment groups

with 10 mice in each group. Volumes of the tumor were estimated every 2 d and the morphology of tumor tissues was observed. Immunohistochemistry was employed to observe the expression of Bcl-2

PCNA

CD31

caspase-3 and caspase-8 in tumor tissues. Results: ApoG2 （2.5 mg/kg-10 mg/kg） given intraperitoneally once a day can obviously inhibit the growth of subcutaneous prostatic carcinoma implant. The tumor volume decreased obviously when the treatment dosage was bigger than 5.0 mg/kg （P<0.01）. Meanwhile

ApoG2 decreased the expression of PCNA and CD31

and enhanced the expression of caspases-3

caspase-8 in tumor tissues. Conclusion: ApoG2 exert an inhibitory effect on prostatic carcinoma possibly by inducing apoptosis and inhibiting tumor angiogenesis.

关键词

Keywords

references

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰